What will be brought about by the sharp price reduction of coronary stents

What kind of results will be brought about by the first national organization of centralized coronary stent procurement? On November 5, the joint purchasing office of high-value medical consumables of the state organization gave an amazing information: the price of stent dropped from about 13000 yuan to about 700 yuan, and it is estimated that 10.9 billion yuan will be saved according to the amount of intention to purchase. Zhong Dongbo, director of the medical price and bidding procurement department of the State Medical Insurance Bureau, said in an interview on the spot that the procurement results exceeded expectations. < / P > < p > a total of 11 enterprises participated in the bidding, and 26 coronary stent products registered and listed in China participated in the bidding. Through competition, 10 products to be selected were produced, belonging to 8 enterprises. Recently, Huo Yong, leader of the cardiovascular intervention management expert group of the National Health Commission, explained in an interview with CCTV “Chaowen Tianxia”, that coronary intervention, that is, stent implantation, is the most effective means to reduce the death of patients with acute myocardial infarction. However, the application of interventional therapy in China is still seriously insufficient. Less than 10% of patients with acute myocardial infarction have received interventional therapy. According to Zhong Dongbo, there are about 3500 coronary stents per million people in Europe and the United States, while only 600 in China. The high price of coronary stent is one of the main factors. Zhong Dongbo stressed that this centralized procurement will not only directly reduce the burden on patients, but also improve the quality of stent use. “After preliminary demonstration and evaluation with experts, alloy materials are more advanced in technology, but there are three or four kinds of stents made of stainless steel due to the cost problem. Through centralized procurement, the price of alloy stents will be greatly reduced, and patients will benefit from it 。” < / P > < p > “the results are exciting.” Zhang Tiejun, director of the joint procurement office of high value medical consumables of the state organization and deputy director of Tianjin Medical Insurance Bureau, introduced that the centralized procurement work summarized the demand for coronary stents in medical institutions across the country, the manufacturers independently declared prices and participated in the market competition, “the lowest bidding price is less than 500 yuan, which shows that the market power is very strong.” According to the introduction, the state organization of centralized procurement of coronary stents has learned from the successful experience of centralized procurement of drugs: first, adhere to the integration of bidding and procurement, and link the quantity and price, so as to stabilize the market expectation of the selected enterprises. Second, adhere to the principle of voluntary participation, independent quotation and fair competition. The third is to adhere to the working mechanism of “state organization, alliance procurement, platform operation”. The State Medical Insurance Bureau and relevant departments formulate policies to form a Procurement Alliance, and Tianjin pharmaceutical procurement center organizes the implementation of procurement. < / P > < p > “the mainstream products commonly used in clinical practice of medical institutions are basically selected, covering more than 70% of the intended purchase volume of medical institutions.” Zhang Tiejun said that both domestic and international well-known enterprises were selected, which satisfied the diversity of doctors and patients. “We will work with the safety and quality supervision department to form a traceability chain from the production, circulation and use of each coronary stent, so that patients can feel free to use it.” Experts from Fuwai Cardiovascular Hospital of Chinese Academy of Medical Sciences, Beijing Anzhen Hospital and Tianjin chest hospital were invited to observe the whole collection, and they all agreed with the results. Professor Liu Zhaoping of the Department of Cardiology, the first hospital of Peking University, said that the use of domestic stents is larger than that of imported stents, and the utilization rate has reached nearly 80%. A lot of clinical experience has been accumulated and the effect has been fully tested. Guo Zhigang, President of Tianjin Chest Hospital, said that centralized purchasing can reduce medical expenses for the common people and reduce medical costs for hospitals. < / P > < p > “the management of high-value medical consumables is not only the deep-water area of reform, but also the hard bone of reform. The medical insurance fund space vacated by the price reduction will maximize the solution to the problem of expensive medical treatment for the masses. ” Zhang Tiejun said that while further standardizing the diagnosis and treatment behavior of medical institutions, the space vacated by the medical insurance fund will also be used for the overall adjustment of medical service prices, so that the value of doctors’ knowledge can be more reflected. Zhong Dongbo said that the centralized collection of coronary stents will also encourage the use of medical institutions through the surplus retention policy. “In areas where DRG payment has been implemented, the payment standard will not be lowered, and the remaining part of medical institutions can be retained; for areas that have not yet implemented DRG payment, such as those paying by project, the medical insurance will provide 50% of the surplus funds to encourage medical institutions.”